Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.
Jul 04, 2024
- Pharmaceuticals
- R&D
Roche Announces Update on Phase II/III SKYSCRAPER-06 Study in Metastatic Non-Squamous Non-Small Cell Lung Cancer
TOKYO, July 4, 2024 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that F. Hoffmann-La Roche Ltd. (SIX: RO, ROG; OTCQX: RHHBY) issued a Media Release today, regarding the update on phase II/III SKYSCRAPER-06 study in metastatic non-squamous non-small cell lung cancer.
Please refer to the link below for details of the Roche’s Media Release:
Roche provides update on phase II/III SKYSCRAPER-06 study in metastatic non-squamous non-small cell lung cancer
https://www.roche.com/media/releases/med-cor-2024-07-04
Contact:
- For Media
- Chugai Pharmaceutical Co., Ltd.
- Media Relations Group, Corporate Communications Dept.,
- Hideki Sato
- Tel: +81-3-3273-0881
- E-mail: pr@chugai-pharm.co.jp
- For Investors
- Chugai Pharmaceutical Co., Ltd.
- Investor Relations Group, Corporate Communications Dept.,
- Takayuki Sakurai
- Tel: +81-3-3273-0554
- E-mail: ir@chugai-pharm.co.jp
